search icon

    Market Snapshot

    • S&P Futures

      3,914.75

    • Dow Futures

      31,478

    • Nasdaq Futures

      12,132.75

    blog search icon

    Adaptimmune Therapeutics plc

    (NASDAQ:ADAP)

    $1.74

    $0.01

    0.58%

    Adaptimmune Therapeutics plc Chart

    ADAP Stock Price Today

    Adaptimmune Therapeutics plc (ADAP) stock rallied over 0.58% intraday to trade at $1.74 a share on NASDAQ. The stock opened with a gain of 1.16% at $1.75 and touched an intraday high of $1.85, rising 0.58% against the last close of $1.73. The stock went to a low of $1.66 during the session.

    Stock Snapshot

    $1.73

    Prev. Close

    253.38 Million

    Market Cap

    $1.66

    Day Low

    $1.75

    Open

    156.67 Million

    Number of Shares

    $1.85

    Day High

    -

    P/E ratio

    -1.09

    EPS (TTM)

    2.36

    Cash Flow per Share

    4.84

    Free Float in %

    1.54

    Book Value

    683,563

    Volume

    Adaptimmune Therapeutics plc Historical Data

    DateOpenHighLowCloseVolume
    2022-06-23$1.75$1.85$1.66$1.74683,800
    2022-06-22$1.72$1.819$1.68$1.73334,800
    2022-06-21$1.79$1.87$1.66$1.68321,000
    2022-06-17$1.58$1.91$1.58$1.781,468,100
    2022-06-16$1.55$1.64$1.525$1.6242,700
    2022-06-15$1.48$1.691$1.48$1.61726,900
    2022-06-14$1.53$1.57$1.46$1.48363,500
    2022-06-13$1.59$1.59$1.44$1.53429,100
    2022-06-10$1.62$1.675$1.57$1.6414,000
    2022-06-09$1.69$1.75$1.646$1.66459,600

    Contact Details

    60 Jubilee Avenue
    Milton Park
    Abingdon OX14 4RX
    United Kingdom

    Webiste:ADAP

    44 12 3543 0000

    Company Information

    Employees-

    Beta1.8

    Sales or Revenue6.15 Million

    5Y Sales Change-15.40%

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. to develop and commercialize allogeneic cell therapies to treat various oncology indications. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

    Frequently Asked Questions

    icon

    What is the current Adaptimmune Therapeutics plc (ADAP) stock price?

    Adaptimmune Therapeutics plc (NASDAQ: ADAP) stock price is $1.74 as of the last check on Thursday, June 23. During the trading session, ADAP stock reached the peak price of $1.85 while $1.66 was the lowest point it dropped to.

    icon

    ADAP's industry and sector of operation?

    The NASDAQ listed ADAP is part of Biotechnology industry that operates in the broader Health Care sector. Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.

    icon

    Who are the executives of ADAP?

    Dr. Arundathy Nirmalini Pandite M.B.A., M.D.
    Sr. VP of Clinical Devel.
    Mr. Adrian G. Rawcliffe
    CEO, Principal Accounting Officer & Director
    Dr. Helen Katrina Tayton-Martin MBA, Ph.D.
    Co-Founder & Chief Bus. Officer
    Mr. Gavin Hilary James Wood BA (Hons), ACA
    Chief Financial Officer

    icon

    What is the ADAP stock price today?

    ADAP stock traded closed the last session at $1.74, which is $0.01 or 0.58% lower than its previous close of $1.73. ADAP's current trading price is 38.10% lower than its 52-week high of $6.86 where as its distance from 52-week low of 1.26% is -74.64%.

    icon

    How many employees does ADAP have?

    Number of ADAP employees currently stands at -. ADAP operates from 60 Jubilee Avenue, Milton Park, Abingdon OX14 4RX, United Kingdom.

    icon

    Link for ADAP official website?

    Official Webiste of $ADAP is: https://www.adaptimmune.com

    icon

    How do I contact ADAP?

    ADAP could be contacted at ADAP operates from 60 Jubilee Avenue, Milton Park, Abingdon OX14 4RX, United Kingdom, or at phone #44 12 3543 0000 and can also be accessed through its website.

    icon

    How many shares of ADAP are traded daily?

    ADAP stock volume for the day was 683,563 shares while in the previous session number of ADAP shares traded was 683,800 . The average number of ADAP shares traded daily for last 3 months was 563.95 Thousands.

    icon

    How much did ADAP change today?

    The percentage change in ADAP stock occurred in the recent session was 0.58% while the dollar amount for the price change in ADAP stock was $0.01.

    icon

    What price range ADAP stock been trading in?

    In the recent session, the day high for ADAP stock was $1.85 while the low for ADAP stock touched on the day was $1.66.

    icon

    What is the market cap of ADAP currently?

    The market value of ADAP currently stands at 253.38 Million with its latest stock price at $1.74 and 156.67 Million of its shares outstanding.